As part of this merger, Sun Pharma acquired all outstanding ordinary shares of Taro other than the shares already held by Sun Pharma or its affiliates. As a result of the merger, Taro will be delisted from the NYSE and it becomes a privately held company 100% owned by Sun Pharma.
